Document:

liventcorpofficerseveran

Livent Corporation  Executive Severance Guidelines for Designated Executives  Background  The intent of these severance guidelines (“Guidelines”) is to provide designated  executives of Livent Corporation (the “Company”) with reasonable transition benefits in  the event of a termination of employment without cause (other than in the context of a  change in control, or as a result of death, disability or retirement).  For this purpose, the  term “designated executive” will have the same meaning as used in the Charter of the  Compensation and Organization Committee of the Company’s Board of Directors (the  “Committee”).  This document is a guideline for the Chief Executive Officer of the  Company and does not create any entitlement for designated executives.  Any deviation  from these Guidelines must be reviewed and approved by the Committee.  Severance Guidelines  Key elements of the Guidelines:  • Severance Pay - Twelve (12) months base salary, payable in a lump sum; - Twelve (12) months of target bonus, payable in a lump sum; and - Prorated target bonus for the year of termination • Medical/Dental Benefits - Twelve (12) months of continued benefits from the termination date at normal employee rates • Long-Term Incentives, Stock Options, Restricted Stock Units and Performance-Based Cash/Equity - Unvested options that would have vested based solely on continued service within one calendar year following termination become exercisable on regularly scheduled dates, and remain exercisable for twelve months thereafter - Twelve (12) months to exercise vested options - Prorated vesting of service-vesting restricted stock units at termination date - PRSUs subject to an open performance period will remain outstanding and be earned (or forfeited) based on actual performance through the end of the performance period, but pro- rated to reflect the portion of the performance period actually worked • Other Transition Benefits - Outplacement assistance ($20K cap) - Vacation pay (earned and unused) - Financial planning assistance for last calendar year of employment - Tax planning for last calendar year of employment Exhibit 10.1 

 

• Conditions  - Designated executive must execute non-compete, non-disclosure  and non-solicitation agreement in a form satisfactory to the Company  - Designated executive must execute and not revoke a release of  claims in a form satisfactory to the Company  Role of the Committee  The Committee approves these Guidelines and any amendments or exceptions  hereto. The Committee should be notified prior to the termination of any designated  executive. These Guidelines will be reviewed periodically to ensure that they are  appropriate and relevant to the market.  Role of Management  Management advises the Committee of any anticipated termination of a designated  executive of the Company, periodically reviews the appropriateness of these  Guidelines, and administers the Guidelines in a fair and evenhanded manner.    Effective Date: August 1, 2022  Livent Corporation 2a4144-2814x72562amendmen

AMENDMENT TO TRANSACTION AGREEMENT AND PLAN OF MERGER This AMENDMENT TO TRANSACTION AGREEMENT AND PLAN OF MERGER  (the “Amendment”) made as of the 25th day of May, 2022 by and among LIVENT  CORPORATION, a Delaware corporation (“Livent”), REACH MERGECO LIMITED, a non- cellular company incorporated in Guernsey with registration number 70586 (“Merger Sub”),  PALLINGHURST LITHIUM LIMITED, a non-cellular company incorporated in Guernsey with  registration number 68222 (“PLL”), PALLINGHURST GP LIMITED, a company incorporated in  the Cayman Islands (“PGPL”), and AMOS CAPITAL LIMITED (formerly known as The  Pallinghurst Group General Partner Limited), a company incorporated in the Cayman Islands  (“ACL”).  RECITALS: WHEREAS the parties to this Amendment are parties to that certain Transaction  Agreement and Plan of Merger dated as of May 2, 2022 (the “Transaction Agreement”); AND WHEREAS pursuant to the Transaction Agreement, Livent agreed to issue  the PLL Note Livent Shares to PGPL, as directed by ACL, and the Carried Interest Livent  Shares to PGPL; AND WHEREAS PGPL and ACL have requested that Livent issue the PLL Note  Livent Shares and the Carried Interest Livent Shares to ACL rather than PGPL, and Livent has  agreed to do so; AND WHEREAS the parties hereto wish to amend the Transaction Agreement as  set forth in this Amendment to reflect that the PLL Note Livent Shares and the Carried Interest  Livent Shares will be issued to ACL rather than PGPL; NOW THEREFORE THIS AMENDMENT WITNESSES THAT in consideration of  the respective covenants and agreements of the parties to this Amendment herein contained  and for other good and valuable consideration (the receipt and sufficiency of which are  acknowledged by each party hereto), the parties hereto agree as follows: 1. Definitions Capitalized terms that are used but not defined in this Amendment, including in the recitals hereto, have the respective meanings specified in the Transaction Agreement. 2. References to TPGGPL (a) ACL represents and warrants to Livent and Merger Sub that its name was changed from “The Pallinghurst Group General Partner Limited” to “Amos Capital Limited” as of  May 10, 2022. (b) All references to “TPGGPL” in the Transaction Agreement are hereby deleted and replaced with references to ACL. (c) The representation and warranty in Section 2(a) of this Amendment shall be deemed to have been made under Article 3 of the Transaction Agreement for all purposes  4165-5175-4552.7 Exhibit 10.3 

 

- 2 - thereof, and such representation and warranty shall be a Fundamental Representation for all  purposes of the Transaction Agreement, subject to, among other things, Section 8.01 (Survival)  and 8.02 (Indemnification).  3. Amendment to Recitals The fifth recital of the Transaction Agreement is hereby deleted in its entirety and  replaced with the following: “WHEREAS, after giving effect to the transactions contemplated  by this Agreement, each of the shareholders of PLL (the “PLL  Shareholders”), which are listed on Schedule A, will continue to  hold an indirect interest in Nemaska through its ownership of  Issued Livent Shares (as defined herein), as will ACL, and ACL or  one of its Affiliates will continue as the “Initial Manager” of  Nemaska as contemplated herein;” 4. Amendment to definition of “Transfer” The references to “PGPL” in the definition of Transfer are hereby deleted and  replaced with references to ACL. 5. Amendment to Section 2.01(a) (The Merger) Section 2.01(a) of the Transaction Agreement is hereby deleted in its entirety and  replaced with the following: “Effective one minute prior to the Effective Time, PLL shall issue  an unsecured promissory note in the principal amount of  $67,343,405 (the “PLL Note”) to ACL in full satisfaction of the  “Performance Incentive” (as defined in the PLL Management  Agreement) and all other fees payable to ACL and its “Associates”  (as defined in the PLL Management Agreement) by PLL in  connection with the transactions contemplated by this Agreement.  PLL and ACL hereby agree that, concurrently with the issuance of  the PLL Note, the PLL Management Agreement shall  automatically terminate without the need for any further act or  formality by either party thereto, following which none of PLL, ACL  or any of their respective Affiliates or any other Person shall have  any rights or obligations, contingent or otherwise, pursuant to the  PLL Management Agreement, including under Section 12.1  thereto.” 6. Amendment to Section 2.06 (Treatment of PLL Note) Section 2.06 of the Transaction Agreement is hereby deleted in its entirety and  replaced with the following: “Treatment of PLL Note.  Effective one minute following the  Effective Time, without any action on the part of any party hereto  or any other Person, Livent shall issue the number of shares set  

 

- 3 - forth opposite “PLL Note Livent Shares” on Schedule H (the “PLL  Note Livent Shares”) to ACL in full satisfaction of the Continuing  Company’s obligations under the PLL Note. At the Closing, Livent  shall deliver evidence of book-entry transfers representing the PLL  Note Livent Shares registered in the name of ACL, and the PLL  Note shall be cancelled.” 7. Amendment to Section 2.07 (Extinguishment of Carried Interest Payment  Obligations) Section 2.07 of the Transaction Agreement is hereby deleted in its entirety and  replaced with the following: “Extinguishment of Carried Interest Payment Obligation.   Upon the terms and subject to the conditions of this Agreement, at  the Effective Time, Livent shall issue the number of shares set  forth opposite “Carried Interest Livent Shares” on Schedule H (the  “Carried Interest Livent Shares”) to ACL, as hereby directed by  PGPL, in full satisfaction of PGPL’s and its Associates’ (as defined  in the QLP SHA) contingent right to receive a portion of the  “Proceeds” pursuant to and as defined in Section 8.2 of the QLP  SHA, following which none of PGPL, Livent USA, Livent or any of  their respective Affiliates or any other Person shall have any rights  or obligations, contingent or otherwise, pursuant to Section 8.2 of  the QLP SHA. At the Closing, Livent shall deliver evidence of  book-entry transfers representing the Carried Interest Livent  Shares registered in the name of ACL.” 8. Amendment to Section 2.08 (Closing) (a) Section 2.08(b) of the Transaction Agreement is hereby deleted in its entirety and  replaced with the following: “Livent shall deliver, or cause to be delivered, to ACL evidence of  book-entry transfers representing the PLL Note Livent Shares and  the Carried Interest Livent Shares registered in the name of ACL.” (b) Section 2.08(c)(ii) of the Transaction Agreement is hereby deleted in its entirety  and replaced with the following: “a properly completed and duly executed Internal Revenue  Service Form W-8 or W-9 in respect of each of the PLL  Shareholders and ACL;” 9. Amendment to Representations and Warranties of PLL, PGPL and ACL (a) The last sentence of Section 3.01 (Corporate Existence and Power; Affiliate) in  the Transaction Agreement is hereby deleted in its entirety and replaced with the following: “ACL and PGPL are not Affiliates of any PLL Shareholder, except  as set forth in Schedule E and ACL is an Affiliate of PGPL. ACL is  

 

- 4 - an “Associate” (as such term is defined in the QLP SHA) of  PGPL.” (b) The representations and warranties of PLL, PGPL and ACL in Section 3.05(b) (Capitalization of PLL), Section 3.07(d) (Assets and Liabilities) and Section 3.10 (Private  Placement) of the Transaction Agreement are hereby amended by deleting the references to  “PGPL” therein and replacing them with references to “ACL”. (c) The second sentence of Section 3.11 (Inspections; No Other Representations) is hereby deleted in its entirety and replaced with the following: “Without limiting the generality of the foregoing, each of PLL,  PGPL and ACL acknowledges that none of Livent nor any of its  Affiliates makes any representation or warranty with respect to (i)  any projections, forecasts or other estimates, plans or budgets  delivered to or made available to PLL, PGPL or ACL or any of  their Affiliates or any of their or such Affiliates’ Representatives of  future revenues, expenses or expenditures, future results of  operations (or any component thereof), future cash flows or future  financial condition (or any component thereof) of Livent or any of  its Subsidiaries or the future business, operations or affairs of  Livent or any of its Subsidiaries or (ii) any other information or  documents made available to PLL, PGPL or ACL or any of their  Affiliates or any of their or such Affiliates’ Representatives with  respect to Livent or any of its Subsidiaries or their respective  businesses or operations (including as to the accuracy and  completeness of any such information), except as expressly set  forth in Article 4.” (d) The representations and warranties of PLL, PGPL and ACL in Section 3.09 (Finders’ Fees) of the Transaction Agreement are hereby amended by deleting the phrase  “Except for the fees payable to PGPL that will be evidenced by the PLL Note and fully settled as  contemplated in this Agreement” and replacing it with the phrase “Except for the fees payable to  ACL that will be evidenced by the PLL Note and fully settled as contemplated in this  Agreement”. 10. Amendments to Representations and Warranties of Livent (a) The reference to “PGPL” in Section 4.07 (Issuance of Issued Livent Shares) is hereby deleted and replaced with a reference to ACL. (b) Section 4.16 (Finders’ Fees) is hereby amended by inserting “, ACL” after the reference to PGPL. 11. Amendment to Section 5.06 (Lock-Up) The references to “PGPL” in Section 5.06 (Lock-Up) of the Transaction Agreement are hereby deleted and replaced with references to ACL. 

 

- 5 - 12. Amendment to Section 6.03 (NYSE Listing) The references to “PGPL” in Section 6.03 (NYSE Listing) of the Transaction  Agreement are hereby deleted and replaced with references to ACL.  13. Amendment to Section 6.10 (Legends) The references to “PGPL” in Section 6.10 (Legends) of the Transaction  Agreement are hereby deleted and replaced with references to ACL. 14. Amendment to Section 6.11 (Rule 144)  The references to “PGPL” in Section 6.11 (Rule 144) of the Transaction  Agreement are hereby deleted and replaced with references to ACL. 15. Amendment to Section 6.14 (Certificate of Non-USRPHC Status) The references to “PGPL” in Section 6.14 (Certificate of Non-USRPHC Status) of  the Transaction Agreement are hereby deleted and replaced with references to ACL. 16. Amendment to Section 7.02 (Conditions to Obligations of Livent and  Merger Sub) Clauses (ii) and (iii) of Section 7.02(a) (Conditions to Obligations of Livent and  Merger Sub) are hereby deleted in their entirety and replaced with the following: “(ii) the representations and warranties of PLL, PGPL and ACL  contained in this Agreement (including any amendment thereto)  and in any certificate or other writing delivered by PLL, PGPL or  ACL pursuant hereto shall be true in all material respects at and  as of the Closing Date as if made at and as of such date and (iii)  Livent shall have received a certificate signed by an officer of PLL,  PGPL and ACL to the foregoing effect”  17. Amendment to Section 7.03 (Conditions to Obligation of PLL and PGPL). Section 7.03 (Conditions to Obligation of PLL and PGPL) is hereby amended by  inserting “, ACL” after each reference to PLL. 18. Amendment to Schedule E (PGPL Affiliate) Schedule E to the Transaction Agreement is hereby amended by deleting the title  of such Schedule and replacing it with “PGPL and ACL Affiliates”, and the reference to  Schedule E to the Transaction Agreement in the table of contents of the Transaction Agreement  is hereby amended by deleting the title of such Schedule and replacing it with “PGPL and ACL  Affiliates”. 19. Amendment to Schedule H (PGPL Livent Shares) Schedule H to the Transaction Agreement is hereby amended by deleting the  title of such Schedule and replacing it with “ACL Livent Shares” and the reference to  Schedule H to the Transaction Agreement in the table of contents of the Transaction Agreement  

 

- 6 - is hereby amended by deleting the title of such Schedule and replacing it with “ACL Livent  Shares”. 20. Effect of Amendment on Transaction Agreement Except as modified by this Amendment, the Transaction Agreement remains  unchanged and in full force and effect.   21. Other Provisions This Amendment hereby incorporates the provisions of Sections 10.04  (Expenses), 10.05 (Successors and Assigns), 10.06 (Governing Law), 10.07 (Jurisdiction),  10.08 (WAIVER OF JURY TRIAL), 10.09 (Counterparts; Effectiveness; Third Party  Beneficiaries), 10.10 (Entire Agreement), 10.11 (Severability) and 10.12 (Specific Performance)  of the Transaction Agreement as if fully set forth herein, mutatis mutandis. [Signature pages follow.] 

 

 

 

       IN WITNESS WHEREOF the parties hereto have caused this Amendment to be  duly executed by their respective authorized officers as of the day and year first written above.    LIVENT CORPORATION  REACH MERGECO LIMITED  by   by    Name:    Name:    Title:    Title:       PALLINGHURST LITHIUM LIMITED     PALLINGHURST GP LIMITED  by   by    Name: Andrew Willis   Name: Andrew Willis   Title: Director   Title: Director      AMOS CAPITAL LIMITED    by     Name: Andrew Willis    Title: Director

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}]]